Continuing Medical Education Information
AACE Endocrine University
Event start date: 02/20/2025
Credit claim deadline: 12/31/2025
Statement of Need
Endocrine University® is designed to provide a forum for endocrinology fellows -in-training to enhance their endocrine curriculum, particularly in diabetes, thyroid, bone, and new technology which has become essential to the practice of endocrinology.
Target Audience:
This program is intended for first year endocrine Fellows-in-Training.
Learning Objectives
By the end of the meeting, participants will be able to:
- Effectively utilize new skills and technology in diabetes and thyroid ultrasound.
- Apply the most up-to-date guidelines and evidence-based practices for the diagnosis and treatment of diabetes and thyroid disease.
- Integrate the latest evidence-based research for diagnosis and treatment of emerging areas of diabetes, thyroid, and bone related practice.
Accreditation and Designation Statements
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Endocrinology (ACE) designates this other (live virtual) activity for a maximum of 16 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure and Conflicts of Interest Policy:
The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
Commercial Support
This activity is supported by educational grants from the following:
- Abbott Diabetes Care
- Novartis Pharmaceuticals
- Lilly USA, LLC
- Novo Nordisk
- Vertex Pharmaceuticals, Inc.
- Corcept Therapeutics
- Medtronic, Inc.
- Recordati Rare Diseases
- Immunovant
- Insulet Corporation
- Xeris Pharmaceuticals
- Ultragenyx Pharmaceuticals
Planning Committee Disclosures
Planner Name
Matthew J. Levine, MD, FACE
Ineligible Company
Novo Nordisk
Recordati
Relevant Financial Relationship
Speakers Bureau
Consultant
Planner Name
Joumana T. Chaiban, MD, MBA, FACE
Ineligible Company
Doximity
Oakstone Publishing
Relevant Financial Relationship
Stock Ownership
Speakers Bureau
Planner Name
Geetha Gopalakrishnan, MD, FACE
Ineligible Company
Medtronic
Sparrow Pharmaceuticals
Spruce Biosciences
Relevant Financial Relationship
Research Funding
Research Funding
Research Funding
Planner Name
Dace Trence, MD, MACE
Ineligible Company
Medtronic
Sanofi
Relevant Financial Relationship
Stock Ownership
Stock Ownership
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Faculty Disclosures
View our faculty disclosures.
View Faculty Disclosures
Reviewers
None of the reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.